Valbenazine (Ingrezza): The First FDA-Approved Treatment for Tardive Dyskinesia

Area of Science:

• Neurology
• Pharmacology

Background:

• Tardive dyskinesia (TD) is a movement disorder often associated with long-term use of dopamine receptor blocking agents.
• Current treatment options for TD have been limited, impacting patient quality of life.

Purpose of the Study:

• To review the efficacy and safety of valbenazine (Ingrezza) as the first FDA-approved treatment for tardive dyskinesia.

Main Methods:

• Review of clinical trial data and FDA approval information for valbenazine.
• Analysis of studies evaluating the impact of valbenazine on abnormal involuntary movement scale (AIMS) scores.

Main Results:

• Valbenazine demonstrated statistically significant reductions in TD symptoms compared to placebo.
• The safety profile of valbenazine was consistent with findings from clinical trials, with common adverse events including somnolence and dry mouth.

Conclusions:

• Valbenazine represents a significant advancement in the management of tardive dyskinesia.
• This approval provides a crucial new therapeutic option for patients suffering from TD.